Generac Soars on Amazon Deal; AutoNation Falls, Ultragenyx Gains FDA Approval


Generac surges after an $8B Amazon generator supply deal; AutoNation slides amid softer demand; Ultragenyx climbs on FDA approval for pediatric gene therapy treating a rare neurodegenerative disease.

Editorial companion

What stands out

Generac's stock spiked after a securities filing showed the company agreed to supply generators to Amazon and issued a warrant that gives Amazon an equity option, a combination that turned a small supplier into a strategic vendor overnight. The move is a reminder that customer relationships can reprice expectations faster than quarterly results can change, which is why headlines still matter to traders. For long-term investors, the episode exposes the gap between market enthusiasm for deal headlines and the underlying profitability that actually compounds over time.